Viking Weight Loss Drug Targets Ozempic And Mounjaro Makers’ Supremacy — What To Know
Viking Therapeutics’ stock more than doubled on Tuesday following the release of trials results suggesting its injectable obesity treatment outperforms industry leaders like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Viking Therapeutics’ stock more than doubled on Tuesday following the release of trials results suggesting its injectable obesity treatment outperforms industry leaders like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
What's Your Reaction?
